Press Release

Printer Friendly Version View printer-friendly version
<< Back
REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following February investor conferences:

SunTrust Robinson Humphrey 2018 Orphan Drug Day
Date: Tuesday, February 13, 2018
Location: JW Marriott Essex House, New York, NY

LEERINK Partners 7th Annual Global Healthcare Conference
Date: Wednesday, February 14, 2018
Location: Lotte New York Palace, New York, NY
Fireside chat: Wednesday, February 14, 2018 at 3:30 p.m. ET

A live webcast of the LEERINK fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com

Primary Logo

REGENXBIO Inc.